Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Carcinoma, Merkel Cell

• Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
• Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
• Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
• A Study of CRD3874-SI in People With Solid Tumors
• Intratumoral PH-762 for Cutaneous Carcinoma
• Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
• Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
• Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
• Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
• Immunological Variables Associated to ICI Toxicity in Cancer Patients
• Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
• Exercise to Boost Response to Checkpoint Blockade Immunotherapy
• L19IL2/L19TNF in Skin Cancer Patients
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
• Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
• A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
• Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
• Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
• Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
• TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
• Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
• Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
• Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
• Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
• Targeted Therapy and Avelumab in Merkel Cell Carcinoma
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
• Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
• Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
• High-Risk Skin Cancers With Atezolizumab Plus NT-I7
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
• This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1/ PD-L1 Immunotherapy
• Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
• Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
• A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
• NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
• A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
• Adjuvant Avelumab in Merkel Cell Cancer
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
• Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
• QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
• Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
• PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
• Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
• Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
• A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
• A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
• Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
• MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
• Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
• Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation
• Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
• F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
• Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
• Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
• A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Me
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Merkel Positron Emission Tomography (PET) Protocol
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
• S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
• Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
• S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
• Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy